<p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在周五的交易中股价创下 52 周新高。该公司股价最高达到 25.59 美元，最后交易价格为 25.46 美元，成交量为 93527 股。该股票此前收盘价为 22.31 美元。</p>
<p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
<h2>分析师评级变动</h2>
<p>多位研究分析师最近对 LYEL 股票发表了看法。HC Wainwright 在 11 月 24 日的研究报告中重申了 “中性” 评级，并将 Lyell Immunopharma 的目标价设定为 20.00 美元（之前为 10.00 美元）。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 Lyell Immunopharma 的 “卖出（d-）” 评级。最后，Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的评级从 “卖出” 上调至 “持有”。一位分析师对该股票给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “减持”，共识目标价为 20.00 美元。</p>
<p><strong>查看我们关于 LYEL 的最新报告</strong></p>
<h2>Lyell Immunopharma 股价上涨 14.1%</h2>
<p>该股票的市值为 5.4021 亿美元，市盈率为-1.11，贝塔值为-0.11。该股票的 50 日移动平均价格为 18.18 美元，200 日移动平均价格为 13.25 美元。</p>
<p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近在 11 月 12 日发布了其财报。该公司报告本季度每股收益为（2.13 美元），超出分析师的共识预期（2.81 美元）0.68 美元。该公司本季度的收入为 0.02 百万美元，而共识预期为 0.01 百万美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。研究分析师预测 Lyell Immunopharma, Inc.本年度每股收益将为-0.78 美元。</p>
<h2>对 Lyell Immunopharma 的对冲基金看法</h2>
<p>几家大型投资者最近增加或减少了对该公司的持股。ARCH Venture Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 现在拥有该公司 2,759,072 股股票，价值 44,807,000 美元，此前在上个季度购买了 938,438 股。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 136.3%。Almitas Capital LLC 现在拥有该公司 2,482,606 股股票，价值 1,336,000 美元，此前在上个季度购买了 1,432,086 股。Vanguard Group Inc.在第三季度将其在 Lyell Immunopharma 的持股增加了 76.0%。Vanguard Group Inc.现在拥有该公司 779,004 股股票，价值 12,651,000 美元，此前在此期间增加了 336,378 股。Acadian Asset Management LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 现在拥有该公司 660,899 股股票，价值 354,000 美元，此前在上个季度增加了 443,614 股。最后，Nuveen LLC 在第一季度购买了 Lyell Immunopharma 的新股份，价值 345,000 美元。对冲基金和其他机构投资者持有该公司 66.05% 的股份。</p>
<h2>关于 Lyell Immunopharma</h2>
<p>（获取免费报告）</p>
<p>Lyell Immunopharma, Inc.是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术（如 c Jun 过表达和 NR4A3 基因敲除）开发疗法，以赋予 T 细胞抵抗疲劳的能力；并利用体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞模拟物。</p>
<h2>了解更多</h2>
<ul>
<li>我们更看好的五只股票比 Lyell Immunopharma 更好</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>Ross Stores 的股票能否在圣诞节前达到 200 美元？分析师认为的三个理由</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>Trade Desk：在下跌 70% 后，现在可能是买入的时机</li>
<li>投资者必须了解场外交易（OTC）股票</li>
<li>利用 2026 年人工智能基础设施的增长，投资于这只高增长 ETF</li>
</ul>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
<p>在你考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Lyell Immunopharma 并不在名单上。</p>
<p>虽然 Lyell Immunopharma 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

LYEL

<p>Lyell Immunopharma（纳斯达克代码：LYEL）股票达到新的 52 周高点，交易价格高达 25.59 美元。尽管股价上涨，分析师的评级却不一，普遍给予 “减持” 评级，目标价为 20.00 美元。该公司报告的收益好于预期，但仍面临重大财务挑战。机构投资者正在调整其持股比例，66.05% 的股票由他们持有。Lyell Immunopharma 专注于开发针对实体肿瘤的 T 细胞重编程技术</p>

<p>Lyell Immunopharma, Inc. (NASDAQ:LYEL - Get Free Report) shares hit a new 52-week high during trading on Friday . The company traded as high as $25.59 and last traded at $25.46, with a volume of 93527 shares traded. The stock had previously closed at $22.31.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.（纳斯达克代码：LYEL - 获取免费报告）在周五的交易中股价创下 52 周新高。该公司股价最高达到 25.59 美元，最后交易价格为 25.46 美元，成交量为 93527 股。该股票此前收盘价为 22.31 美元。</p>
</div><p>Get <strong>Lyell Immunopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Lyell Immunopharma</strong> 的提醒：</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts recently weighed in on LYEL shares. HC Wainwright reaffirmed a &#34;neutral&#34; rating and set a $20.00 price objective (up previously from $10.00) on shares of Lyell Immunopharma in a research report on Monday, November 24th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Lyell Immunopharma in a research note on Wednesday, October 8th. Finally, Wall Street Zen raised Lyell Immunopharma from a &#34;sell&#34; rating to a &#34;hold&#34; rating in a research report on Monday, September 1st. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of &#34;Reduce&#34; and a consensus price target of $20.00.</p>
<div class="lb-trans"><p>多位研究分析师最近对 LYEL 股票发表了看法。HC Wainwright 在 11 月 24 日的研究报告中重申了 “中性” 评级，并将 Lyell Immunopharma 的目标价设定为 20.00 美元（之前为 10.00 美元）。Weiss Ratings 在 10 月 8 日的研究报告中重新发布了 Lyell Immunopharma 的 “卖出（d-）” 评级。最后，Wall Street Zen 在 9 月 1 日的研究报告中将 Lyell Immunopharma 的评级从 “卖出” 上调至 “持有”。一位分析师对该股票给予了 “持有” 评级，另一位则给予了 “卖出” 评级。根据 MarketBeat 的数据，该公司的共识评级为 “减持”，共识目标价为 20.00 美元。</p>
</div><p><strong>Check Out Our Latest Report on LYEL</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 LYEL 的最新报告</strong></p>
</div><h2>Lyell Immunopharma Trading Up 14.1%</h2>
<div class="lb-trans"><h2>Lyell Immunopharma 股价上涨 14.1%</h2>
</div><p>The stock has a market capitalization of $540.21 million, a PE ratio of -1.11 and a beta of -0.11. The stock has a 50 day moving average price of $18.18 and a 200-day moving average price of $13.25.</p>
<div class="lb-trans"><p>该股票的市值为 5.4021 亿美元，市盈率为-1.11，贝塔值为-0.11。该股票的 50 日移动平均价格为 18.18 美元，200 日移动平均价格为 13.25 美元。</p>
</div><p>Lyell Immunopharma (NASDAQ:LYEL - Get Free Report) last posted its earnings results on Wednesday, November 12th. The company reported ($2.13) earnings per share for the quarter, beating analysts' consensus estimates of ($2.81) by $0.68. The company had revenue of $0.02 million for the quarter, compared to the consensus estimate of $0.01 million. Lyell Immunopharma had a negative return on equity of 96.68% and a negative net margin of 794,292.69%. Research analysts forecast that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.</p>
<div class="lb-trans"><p>Lyell Immunopharma（纳斯达克代码：LYEL - 获取免费报告）最近在 11 月 12 日发布了其财报。该公司报告本季度每股收益为（2.13 美元），超出分析师的共识预期（2.81 美元）0.68 美元。该公司本季度的收入为 0.02 百万美元，而共识预期为 0.01 百万美元。Lyell Immunopharma 的股本回报率为-96.68%，净利润率为-794,292.69%。研究分析师预测 Lyell Immunopharma, Inc.本年度每股收益将为-0.78 美元。</p>
</div><h2>Hedge Funds Weigh In On Lyell Immunopharma</h2>
<div class="lb-trans"><h2>对 Lyell Immunopharma 的对冲基金看法</h2>
</div><p>Several large investors have recently added to or reduced their stakes in the company. ARCH Venture Management LLC increased its stake in shares of Lyell Immunopharma by 51.5% in the third quarter. ARCH Venture Management LLC now owns 2,759,072 shares of the company's stock worth $44,807,000 after purchasing an additional 938,438 shares in the last quarter. Almitas Capital LLC increased its stake in Lyell Immunopharma by 136.3% in the 1st quarter. Almitas Capital LLC now owns 2,482,606 shares of the company's stock worth $1,336,000 after buying an additional 1,432,086 shares in the last quarter. Vanguard Group Inc. raised its holdings in Lyell Immunopharma by 76.0% during the third quarter. Vanguard Group Inc. now owns 779,004 shares of the company's stock valued at $12,651,000 after acquiring an additional 336,378 shares during the period. Acadian Asset Management LLC grew its stake in Lyell Immunopharma by 204.2% during the first quarter. Acadian Asset Management LLC now owns 660,899 shares of the company's stock valued at $354,000 after acquiring an additional 443,614 shares in the last quarter. Finally, Nuveen LLC bought a new stake in Lyell Immunopharma in the 1st quarter valued at $345,000. Hedge funds and other institutional investors own 66.05% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近增加或减少了对该公司的持股。ARCH Venture Management LLC 在第三季度将其在 Lyell Immunopharma 的持股增加了 51.5%。ARCH Venture Management LLC 现在拥有该公司 2,759,072 股股票，价值 44,807,000 美元，此前在上个季度购买了 938,438 股。Almitas Capital LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 136.3%。Almitas Capital LLC 现在拥有该公司 2,482,606 股股票，价值 1,336,000 美元，此前在上个季度购买了 1,432,086 股。Vanguard Group Inc.在第三季度将其在 Lyell Immunopharma 的持股增加了 76.0%。Vanguard Group Inc.现在拥有该公司 779,004 股股票，价值 12,651,000 美元，此前在此期间增加了 336,378 股。Acadian Asset Management LLC 在第一季度将其在 Lyell Immunopharma 的持股增加了 204.2%。Acadian Asset Management LLC 现在拥有该公司 660,899 股股票，价值 354,000 美元，此前在上个季度增加了 443,614 股。最后，Nuveen LLC 在第一季度购买了 Lyell Immunopharma 的新股份，价值 345,000 美元。对冲基金和其他机构投资者持有该公司 66.05% 的股份。</p>
</div><h2>About Lyell Immunopharma</h2>
<div class="lb-trans"><h2>关于 Lyell Immunopharma</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.</p>
<div class="lb-trans"><p>Lyell Immunopharma, Inc.是一家临床阶段的细胞治疗公司，开发针对实体肿瘤患者的 T 细胞重编程技术。该公司利用体外基因重编程技术（如 c Jun 过表达和 NR4A3 基因敲除）开发疗法，以赋予 T 细胞抵抗疲劳的能力；并利用体外表观遗传重编程技术，包括 Epi R 以生成具有持久干性的人群 T 细胞，以及 Stim R，一种专有合成细胞模拟物。</p>
</div><h2>Read More</h2>
<div class="lb-trans"><h2>了解更多</h2>
</div><ul>
<li>Five stocks we like better than Lyell Immunopharma</li>
<li>Investing in Commodities: What Are They? How to Invest in Them</li>
<li>Could Ross Stores Stock Hit $200 by Christmas? Here Are 3 Reasons Analysts Think So</li>
<li>How Investors Can Find the Best Cheap Dividend Stocks</li>
<li>The Trade Desk: After a 70% Plunge, This Could Be The Time to Buy</li>
<li>What Investors Must Know About Over-the-Counter (OTC) Stocks</li>
<li>Tap Into 2026 AI Infrastructure Gains With This High-Growth ETF</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Lyell Immunopharma 更好</li>
<li>投资商品：它们是什么？如何投资？</li>
<li>Ross Stores 的股票能否在圣诞节前达到 200 美元？分析师认为的三个理由</li>
<li>投资者如何找到最佳的便宜股息股票</li>
<li>Trade Desk：在下跌 70% 后，现在可能是买入的时机</li>
<li>投资者必须了解场外交易（OTC）股票</li>
<li>利用 2026 年人工智能基础设施的增长，投资于这只高增长 ETF</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Lyell Immunopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Lyell Immunopharma 吗？</h2>
</div><p>Before you consider Lyell Immunopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Lyell Immunopharma 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lyell Immunopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已经识别出五只股票，顶级分析师正在悄悄地向他们的客户推荐，现在就买入，以便在更广泛的市场注意到之前……而 Lyell Immunopharma 并不在名单上。</p>
</div><p>While Lyell Immunopharma currently has a Reduce rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Lyell Immunopharma 目前在分析师中获得了减持评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Lyell Immunopharma（NASDAQ:LYEL）创下 12 个月新高——现在是买入的时机吗？